Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Cancer Cell|November 14, 2018
JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor CellsHamza Celik, Won Kyun Koh, Ashley C Kramer, et al.
Nature Cancer|December 29, 2022
DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progressionTim Kong, Angelo B A Laranjeira, Kangning Yang, et al.
Blood Advances|September 11, 2020
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trialStephen T Oh, Moshe Talpaz, Aaron T Gerds, et al.
Cancer Discovery|July 1, 2021
A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative NeoplasmsHamza Celik, Ethan Krug, Christine R Zhang, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With MomelotinibClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
The Journal of Clinical Investigation|December 7, 2023
Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasmsFan He, Angelo Ba Laranjeira, Tim Kong, et al.
Hemasphere|November 1, 2023
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 TrialsJean-Jacques Kiladjian, Alessandro M Vannucchi, Aaron T Gerds, et al.
Blood Advances|August 8, 2023
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosisStephen T Oh, Ruben A Mesa, Claire N Harrison, et al.
Science Translational Medicine|September 23, 2016
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemiaRizwan Romee, Maximillian Rosario, Melissa M Berrien-Elliott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2024
Plasma Proteomic Signature Predicts Myeloid Neoplasm RiskDuc Tran, J Scott Beeler, Jie Liu, et al.
Pageof 10